Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

Pages

23023 items
12:29 PM, Jun 15, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Flex downsizing on troubles with sole clinical program

Flex Pharma Inc. (NASDAQ:FLKS) said it is cutting headcount by about 60% after discovering its sole clinical program, FLX-787, will require additional work that stretch beyond the biotech's current means. Flex said it will evaluate...
12:21 PM, Jun 08, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Osaka University starts trial of iPS cell-derived cardiomyocyte sheets

Researchers at Osaka University (Osaka, Japan) started a clinical trial evaluating an induced pluripotent stem (iPS) cell-based therapy to treat severe ischemic cardiomyopathy. The trial will assess safety and change in cardiac function. The therapy...
12:19 PM, Jun 08, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

BlackThorn brings KOR antagonist into clinic

BlackThorn Therapeutics Inc. (San Francisco, Calif.) began a Phase I trial evaluating up to seven single and multiple ascending doses of BTRX-335140 to assess dose exposure and safety in about 90 healthy volunteers. The company...
11:27 AM, Jun 08, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Roche discontinues SMA candidate

Roche (SIX:ROG; OTCQX:RHHBY) said it will discontinue development of spinal muscular atrophy candidate olesoxime (RG6083, TRO19622). In April, Roche presented data at the American Academy of Neurology meeting in Los Angeles from the long-term follow-up...
12:02 PM, Jun 01, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Janssen to bring Legend CAR T into clinic

Janssen Biotech Inc. said FDA cleared an IND for CAR T therapy JNJ-68284528 (LCAR-B38M) to treat multiple myeloma. Next half, the unit of Johnson & Johnson (NYSE:JNJ) expects to start a U.S. and European Phase...
11:23 AM, May 25, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Janssen discontinues two Alzheimer's trials for BACE inhibitor

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said it is discontinuing two trials testing atabecestat (JNJ-54861911) to treat Alzheimer's disease after an evaluation showed the therapy led to elevated liver enzyme levels....
11:23 AM, May 25, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
1:07 PM, May 18, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...
12:42 PM, May 18, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Novartis to start head-to-head trial of Cosentyx and Tremfya

Novartis AG (NYSE:NVS; SIX:NOVN) plans to begin the head-to-head Phase IIa ARROW trial to compare Cosentyx secukinumab to Tremfya guselkumab for 16 weeks in 40 patients with Stelara ustekinumab-resistant plaque psoriasis. The pharma expects to...
11:50 AM, May 04, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Incyte 'downsizing' IDO1 program, ends some combo trials

Incyte Corp. (NASDAQ:INCY) said it is "downsizing" its program evaluating epacadostat, its indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. The company plans to halt enrollment of six pivotal trials of epacadostat in combination with anti-PD-1 mAbs Keytruda...

Pages